{"id":"oxycodone-naltrexone-a","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Drowsiness"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Oxycodone binds to mu-opioid receptors to produce analgesia and pain relief. Naltrexone, an opioid antagonist, is included in the formulation to block some opioid effects and theoretically reduce constipation, respiratory depression, and abuse liability. The combination aims to maintain analgesic efficacy while mitigating common opioid side effects.","oneSentence":"Oxycodone naltrexone is a combination of an opioid agonist (oxycodone) and an opioid antagonist (naltrexone) designed to provide analgesia while reducing opioid-related adverse effects and abuse potential.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:25:15.170Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate to severe chronic pain"}]},"trialDetails":[{"nctId":"NCT06500793","phase":"PHASE1","title":"Single Dose Study, Pharmacokinetics of Oxycodone and PF614 Co-Administered With Nafamostat (PF614-MPAR-102)","status":"RECRUITING","sponsor":"Ensysce Biosciences","startDate":"2024-11-24","conditions":"Pharmacokinetics","enrollment":30},{"nctId":"NCT02454712","phase":"PHASE1","title":"Study of PF614 Compared to OxyContin® in Healthy Volunteers (PF614-101)","status":"COMPLETED","sponsor":"Ensysce Biosciences","startDate":"2016-11-16","conditions":"Healthy","enrollment":64},{"nctId":"NCT05090280","phase":"PHASE1","title":"Pharmacokinetics of Oxycodone and PF614 Co-Administered with Nafamostat (PF614-MPAR-101)","status":"COMPLETED","sponsor":"Ensysce Biosciences","startDate":"2021-12-01","conditions":"Pharmacokinetics","enrollment":111},{"nctId":"NCT05043766","phase":"PHASE1","title":"Evaluation of Oral PF614 Relative to OxyContin (PF614-102)","status":"COMPLETED","sponsor":"Ensysce Biosciences","startDate":"2021-09-08","conditions":"Healthy Volunteers","enrollment":84},{"nctId":"NCT01746901","phase":"PHASE1","title":"A Study to Characterize the Abuse Liability of ALO-02 in Healthy, Non-Dependent, Recreational Opioid Abusers","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-02","conditions":"Healthy","enrollment":81},{"nctId":"NCT01677065","phase":"","title":"A Randomized, Two-way, Crossover Study to Estimate the Relative Bioavailability of a Controlled-release Formulation of Oxycodone (40 mg) With Sequestered Naltrexone Compared With Immediate-release Oxycodone Tablets (20 mg) in Healthy Volunteers","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-09","conditions":"Healthy","enrollment":14},{"nctId":"NCT01456507","phase":"PHASE1","title":"Healthy Volunteers Study to Estimate the Effects of Food on the Bioavailability of Oxycodone and Naltrexone/6- Β -Naltrexol From a Extended Release Formulation of Oxycodone With Sequestered Naltrexone","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-10","conditions":"Healthy","enrollment":24},{"nctId":"NCT02680847","phase":"PHASE4","title":"Safety and Pharmacokinetic Study of ALO-02 in Children Ages 7-17 With Pain","status":"TERMINATED","sponsor":"Pfizer","startDate":"2016-01-21","conditions":"Moderate-severe Pain","enrollment":32},{"nctId":"NCT01775189","phase":"PHASE1","title":"A Study to Characterize the Abuse Liability of ALO-02 in Healthy, Non-Dependent, Recreational Opioid Users When ALO-02 Capsules Are Crushed and Snorted","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-02","conditions":"Healthy","enrollment":45},{"nctId":"NCT01571362","phase":"PHASE3","title":"A Research Study of an Investigational Drug ALO-02 (Oxycodone Hydrochloride and Naltrexone Hydrochloride) in Patients With Moderate to Severe Chronic Low Back Pain","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-06","conditions":"Chronic Pain, Low Back Pain, Analgesia","enrollment":410},{"nctId":"NCT01428583","phase":"PHASE3","title":"Safety Study of Oxycodone Hydrochloride and Naltrexone Hydrochloride Extended-Release Capsules in Subjects With Moderate to Severe Chronic Noncancer Pain","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-12","conditions":"Chronic Noncancer Pain","enrollment":395},{"nctId":"NCT02391571","phase":"PHASE3","title":"A Study to Evaluate Withdrawal Effects Following Dosing of Oxycodone/Naltrexone in Methadone-Maintained Subjects","status":"COMPLETED","sponsor":"Elite Laboratories, Inc","startDate":"2015-02","conditions":"Withdrawal Symptoms","enrollment":26},{"nctId":"NCT02401750","phase":"PHASE3","title":"A Study to Evaluate Safety and Efficacy Following Dosing of Oxycodone/Naltrexone for Treatment of Adults With Pain Following Bunionectomy Surgery","status":"COMPLETED","sponsor":"Elite Laboratories, Inc","startDate":"2015-06","conditions":"Pain","enrollment":163},{"nctId":"NCT00734461","phase":"PHASE2","title":"Study to Evaluate the Subjective Effects of PTI-801 in Non-Physically Dependent Subjects With a History of Drug Abuse","status":"COMPLETED","sponsor":"Pain Therapeutics","startDate":"2007-08","conditions":"Opioid-Related Disorders","enrollment":14},{"nctId":"NCT02117583","phase":"PHASE1","title":"Effects of Food on Oxycodone Pharmacokinetics in Healthy Volunteers","status":"COMPLETED","sponsor":"Pain Therapeutics","startDate":"2014-04","conditions":"Healthy","enrollment":34},{"nctId":"NCT02165930","phase":"PHASE1","title":"Effects of Ethanol on Oxycodone Pharmacokinetics in Healthy Volunteers","status":"COMPLETED","sponsor":"Pain Therapeutics","startDate":"2014-07","conditions":"Healthy","enrollment":17},{"nctId":"NCT02089295","phase":"PHASE1","title":"Dose Proportionality Study Of PF-00345439 Formulation Under Fed Conditions","status":"COMPLETED","sponsor":"Pain Therapeutics","startDate":"2014-04","conditions":"Healthy","enrollment":18},{"nctId":"NCT02059915","phase":"PHASE1","title":"Single-Dose, Crossover Study To Compare Bioavailability Of Two Formulations Under Fed And Fasted Conditions","status":"COMPLETED","sponsor":"Pain Therapeutics","startDate":"2014-04","conditions":"Healthy","enrollment":134},{"nctId":"NCT01717027","phase":"PHASE1","title":"Pharmacokinetics And Relative Bioavailability Study Of Oxycodone in Healthy Volunteers","status":"COMPLETED","sponsor":"Pain Therapeutics","startDate":"2012-11","conditions":"Healthy","enrollment":19},{"nctId":"NCT01552850","phase":"PHASE1","title":"Pharmacokinetics And Relative Bioavailability Study Of Oxycodone","status":"COMPLETED","sponsor":"Pain Therapeutics","startDate":"2012-04","conditions":"Pain","enrollment":18},{"nctId":"NCT01924676","phase":"PHASE1","title":"Food Effect And Relative Bioavailability Study Of Oxycodone in Healthy Volunteers","status":"COMPLETED","sponsor":"Pain Therapeutics","startDate":"2013-08","conditions":"Healthy","enrollment":18},{"nctId":"NCT01552863","phase":"PHASE1","title":"A Study To Characterize The Pharmacokinetics Of Oxycodone In Healthy Volunteers","status":"COMPLETED","sponsor":"Pain Therapeutics","startDate":"2012-03","conditions":"Pain","enrollment":21},{"nctId":"NCT01825447","phase":"PHASE1","title":"A Study to Characterize the Abuse Liability of Intravenous Oxycodone Alone or in Combination With Intravenous Naltrexone in Healthy, Non-Dependent, Recreational Opioid Users","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-07","conditions":"Healthy","enrollment":89},{"nctId":"NCT01677039","phase":"PHASE1","title":"Study to Determine the Effects of Co-Administration of Alcohol on the Absorption of Oxycodone From a Proprietary Controlled-Release Formulation","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-09","conditions":"Healthy","enrollment":19}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Oxycodone Naltrexone (a)","genericName":"Oxycodone Naltrexone (a)","companyName":"Elite Laboratories, Inc","companyId":"elite-laboratories-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Oxycodone naltrexone is a combination of an opioid agonist (oxycodone) and an opioid antagonist (naltrexone) designed to provide analgesia while reducing opioid-related adverse effects and abuse potential. Used for Moderate to severe chronic pain.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}